论文部分内容阅读
目的为探讨白血病患者外周血单个核细胞（ＰＭＮＣ）上白细胞介素２膜受体（ｍＩＬ－２Ｒ）的表达及临床价值。方法采用流式细胞仪对１４例急性淋巴细胞白血病（ＡＬＬ），２６例急性髓细胞白血病（ＡＭＬ），１９例有骨髓异常增生综合症病史的ＡＭＬ（ＭＤＳ－ＡＭＬ）及２６例慢粒急变（ＣＭＬ·ＢＣ）患者的ＰＭＮＣ上ｍＩＬ－２Ｒ的表达进行了检测。结果ＭＤＳ－ＡＭＬ及慢粒急粒变患者ｍＩＬ－２Ｒ的表达明显高于ＡＭＬ（Ｐ＜０．０１，Ｐ＜０．０５）。慢粒急淋变患者ｍＩＬ－２Ｒ的表达明显高于ＡＬＬ（Ｐ＜０．０５）。ｍＩＬ－２Ｒ阳性ＡＭＬ及ＡＬＬ患者对化疗反应性较差。结论ｍＩＬ－２Ｒ的表达可能为ＭＤＳ－ＡＭＬ，ＣＭＬ·ＢＣ的一个特征，并可作为估计ＡＭＬ、ＡＬＬ疗效的一项指标
Objective To investigate the expression and clinical value of interleukin-2 receptor (mIL-2R) on peripheral blood mononuclear cells (PMNC) in patients with leukemia. Methods Flow cytometry was used in 14 cases of acute lymphoblastic leukemia (ALL), 26 cases of acute myeloid leukemia (AML), 19 cases of AML (MDS-AML) with a history of myelodysplastic syndrome and 26 cases of chronic granuloma. The expression of mIL-2R on PMNC in patients with CML and BC) was examined. Results The expression of mIL-2R was significantly higher in patients with MDS-AML and chronic granuloma than that in AML (P<0.01, P<0.05). The expression of mIL-2R in patients with acute granuloma was significantly higher than that of ALL (P<0.05). mIL-2R positive AML and ALL patients have poor response to chemotherapy. Conclusion The expression of mIL-2R may be a characteristic of MDS-AML, CML, and BC, and may be used as an index to estimate the efficacy of AML and ALL.